HBV, HCV Reactivation During Chemotherapy of ConcernMedscapeRecommendations from ASCO are less comprehensive: Only those about to undergo "highly" immunosuppressive regimens (ie, stem cell transplants or treatment with rituximab) and patients…
BBC NewsVIDEO: MP backs woman's NHS drug fightBBC NewsPenny Wheeler, who has an incurable auto-immune disease called scleroderma and pulmonary fibrosis, should get rituximab on the health service, Conservative MP for Mid Derbyshire, Pauline Latham,…
First-Time Guidelines for Lupus Nephritis: Biopsy for AllMedscapeThe guidelines, presented here at the American College of Rheumatology (ACR) 2011 Annual Meeting, also recommend the use of a biologic drug for refractive disease, although the drug, ritu…
Clinical Oncology NewsStudy Gives Slight Edge to R-DHAP for B-Cell Lymphoma SubtypeClinical Oncology NewsWhen CORAL was first presented, not only were we disappointed that neither R-ICE nor R-DHAP proved superior, we were devastated to learn how poorly…
Pfizer To Present Clinical Data From Its Hematology Portfolio At The 53rd …MarketWatch (press release)(13,14) Inotuzumab is currently being evaluated in a Phase 3 study in combination with rituximab in patients with relapsed or refractory CD22-positi…
Recent Multiple Sclerosis Market Events Have Resulted in Treatment Algorithm …MarketWatch (press release)Patient profiles for the seven DMAs in late clinical development (alemtuzumab, BG-12, teriflunomide, laquinimod, PEG-Avonex, daclizumab, ocrelizu…
Save time and money withMTBeurope(infliximab), Humira (adalimumab) and Rituxan (rituximab). The growth was further fuelled by the launch of safer and more efficacious biologics. During 2010-2018, the rheumatoid arthritis therapeutics market is expected…
Biogen Idec: Q3 Clues To ValueSeeking AlphaIn addition Daclizumab HYP showed good Phase 2b trial results. Dexpramipexole for Lou Gehrig's (ALS) disease Phase III trial became fully enrolled recently. Third quarter (Q3) results released on October 2…
Promising new treatments on the horizonMS TrustDaclizumab, also known as Zenepax, is a monoclonal antibody already licensed for prevention of kidney transplant rejection. The SELECT trial tested subcutaneous (under the skin) injections of either placeb…
The Rituximab Story: not evidence for XMRV and NOT a potential autism therapyLeft Brain/Right BrainUnfortunately, in an attempt to revive the XMRV/autism link, Kent Heckenlively of the Age of Autism blog is creating a new, dangerous conclusion: perhaps…